MTRI Stock Analysis Today

Updated Nov 20, 2026 · trends, key levels, insider activity and news

$15.24-$0.04 (-0.26%)close Nov 19, 2026

Is MTRI bullish or bearish today?

Daily trend: Neutral

SEPT signal: Accumulation · Consolidating

Research grade: B+ · fair value $30.00 (+96.8%)

MTRI trend by timeframe

DailyNeutral
4 hourStrong Bearish
1 hourStrong Bearish
15 minSymmetric Triangle
5 minStrong Bearish

Trends are calculated from price structure and update during market hours.

Latest MTRI news and filings

  • AnalystBenzinga

    Wedbush starts Mentari Therapeutics coverage with Outperform rating and $33 price target

    Wedbush began covering Mentari Therapeutics with an Outperform rating. The firm set a $33 price target on the shares.

  • AnalystBenzinga

    Jefferies starts Mentari Therapeutics coverage with Buy rating and $30 price target

    Jefferies began covering Mentari Therapeutics and gave the shares a Buy rating. The firm set a $30 price target on the stock.

  • AnalystBenzinga

    Stifel starts Mentari Therapeutics coverage with Buy rating and $30 price target

    Stifel began covering Mentari Therapeutics and rated the shares Buy. The firm set a $30 price target on the stock.

All MTRI news from the last 90 days →
SEPT InvestingBeta Pioneer $29.99/mo until Jan 2, 2027

Live MTRI chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.

Start free 7-day trial

Frequently asked questions

Is MTRI bullish or bearish today?

MTRI daily trend: Neutral. SEPT signal: Accumulation (Consolidating). Updated Nov 20, 2026.

What is MTRI's trend on each timeframe?

Daily: Neutral; 4 hour: Strong Bearish; 1 hour: Strong Bearish; 15 min: Symmetric Triangle; 5 min: Strong Bearish.

What is the latest news on MTRI?

Nov 13, 2026: Wedbush starts Mentari Therapeutics coverage with Outperform rating and $33 price target · Nov 10, 2026: Jefferies starts Mentari Therapeutics coverage with Buy rating and $30 price target · Nov 10, 2026: Stifel starts Mentari Therapeutics coverage with Buy rating and $30 price target